Marshall Wace’s LENZ Therapeutics LENZ Stock Holding History

Marshall Wace’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.47M	Buy	160,264 +125,012	+355%	+$1.76M	﹤0.01%	1953
2025 Q4	$564K	Buy	+35,252	New	+$1.03M	﹤0.01%	2190
2024 Q3	–	Sell	-22,554	Closed	-$390K	–	3031
2024 Q2	$390K	Buy	+22,554	New	+$394K	﹤0.01%	2054
2023 Q2	–	Sell	-5,844	Closed	-$100K	–	3043
2023 Q1	$100K	Buy	+5,844	New	+$94.5K	﹤0.01%	2499
2022 Q3	–	Sell	-7,235	Closed	-$139K	–	3877
2022 Q2	$139K	Buy	+7,235	New	+$161K	﹤0.01%	3232

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Marshall Wace's LENZ Position: Q1 2026 in Review

Marshall Wace increased its LENZ Therapeutics (LENZ) stake by 355% in Q1 2026, buying an estimated $1.76M and bringing the position to 160,264 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Marshall Wace first reported a position in LENZ in Q2 2022 and has held it in 5 quarters since. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Marshall Wace held 160,264 shares of LENZ Therapeutics worth $1.47M as of Q1 2026.
Marshall Wace bought 125,012 LENZ Therapeutics shares in Q1 2026, an estimated $1.76M.
LENZ Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1953 holding.
Marshall Wace first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 5 quarters since.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.